The MyWay programme gives patients additional support when taking DUPIXENT


The range of services provided are entirely optional and aim to provide assistance to healthcare teams managing the treatment of patients through:

HOMECARE

 

Registration for
home delivery

NURSE
TRAINING VISITS

 

Homecare nurse visits to train patients on self-administration

ONGOING
SUPPORT

 

Support calls and
quarterly reviews

TEXT MESSAGING
REMINDER

 

Reminders for injections,
deliveries and nurse visits

Other features


Digital starter kits for adults, adolescents and children, to provide them with the correct tools so they can start their DUPIXENT journey.

These include:

Patient information guides

QR codes to access the on-the-go microsites

Virtual reality (VR) glasses

Comics and wallcharts

Parent or carer information guide

Immune micropilots game

EZTrack for Atopic Dermatitis is a free mobile app allowing patients to monitor, track, and manage their AD.

Create photo libraries which track the evolution of lesions over time

Tips and advice on AD and its management

DLQI and POEM assessments to help log itchiness severity, sleep disturbance and potential triggers

Develop report summaries to help navigate productive conversations

Learn more about the Patient Support Programme



Overview of AD

Find out more about how AD has a continuous inflamation cycle.




Find out more


Request a representative call

Have aquestion about DUPIXENT?
Get answers from a representative.




Find out more


Dosing

Learn more about how to administer DUPIXENT.





Find out more

    AD, atopic dermatitis; γC, gamma C subunit; IL, interleukin; IL-4Rα; Interleukin 4 receptor alpha;  IL-13Rα1, interleukin 13 receptor alpha 1;  ILC,  innate lymphoid cells;  JAK, Janus kinase; 
    Th,
    T-helper cells;  TYK2, tyrosine kinase 2.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155–172.
    3. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    4. D’Erme A, et al. Drug Des Devel Ther. 2017;11:1473–1480.
    5. McCormick M, et al. Cytokine. 2015;75(1):38–50.

MAT-IE-2101040(v4.0) | Date of preparation: February 2022